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Abstract
The phosphoinositol-3 kinase (PI3K) pathway is highly dysregulated in squamous cell carcinoma of the head and neck
(SCCHN). While inhibitors of the PI3K/AKT pathway are being developed in cancer, their efficacy does not appear to be
related to the presence of mutations or amplification in pathway genes. The PI3K pathway is a major regulator of macro-
autophagy, an evolutionarily conserved catabolic process that degrades cellular materials to promote cellular homeostasis
and survival under stress. Employing a panel of SCCHN cell lines, we observed a significant correlation between the activity
of PI3K/AKT inhibitors and their ability to induce autophagy. More specifically, resistance to these inhibitors was associated
with accumulation of p62/SQSTM1, a pleotropic protein that is consumed during autophagy, while loss of autophagy was,
for the first time, found to be due to silencing of an essential autophagy gene, ATG7. Moreover, modulating ATG7 and p62/
SQSTM1 could regulate sensitivity to PI3K/AKT inhibitors, underscoring a mechanistic link between autophagy and drug
sensitivity. Analysis of human tissues revealed progressive accumulation of p62/SQSTM1 in a significant proportion of
cancer samples compared to normal tissue, suggesting that defective autophagy has relevance to SCCHN. These findings
are further validated by analysis of TCGA data confirming homozygous deletion and mRNA down-regulation of ATG7 in
10.0% of SCCHN samples. Taken together, these data indicate that p62/SQSTM1 levels modulate sensitivity to PI3K/AKT
inhibitors; cancers vary in their capacity to undergo autophagy through epigenetic modification and, when deficient,
accumulate p62/SQSTM1; and expression of autophagy-related proteins may serve as markers for resistance to PI3K/AKT
inhibitors in SCCHN.
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Introduction
The phosphotidylinositol-3 kinase (PI3K) signaling pathway is a
key regulator of cellular growth and stress responses that is
constitutively activated in many cancers [1]. Specific mutations or
copy number variations in PI3K pathway components, in addition
to other pathway alterations have been discovered in almost every
human malignancy analyzed [2,3]. These findings have driven the
development of PI3K pathway inhibitors that include specific
inhibitors of PI3K subunit 3, specific AKT inhibitors as well as
inhibitors of mTORC1 and mTORC2 [4,5]. Paradoxically,
despite the relative success of some of these pathway inhibitors
in clinical trials, alterations in the pathway are neither sufficient
nor necessary for response to these agents and reliable biomarkers
that predict successful therapeutic efficacy for these agents have
been lacking [6,7].
Squamous Cell Carcinoma of the Head and Neck (SCCHN) is
the 6th most common malignancy worldwide [8] with a worldwide
incidence of at least 500,000 and will be diagnosed in approxi-
mately 45,000 new patients in the United States this year [9].
Furthermore, population data from the United States demonstrate
that some types of SCCHN, those associated with Human
Papillomavirus infection, have been dramatically increasing in
incidence in recent years [10], indicating that SCCHN is likely to
become a yet more pressing health challenge in the future. It is
now clear from DNA sequencing and gene copy number data that
SCCHN tumors harbor amongst the highest rate of PI3K pathway
genomic alteration of any malignancy [11–15]. Inhibitors of this
pathway, therefore, have promise in SCCHN and are being
actively developed.
Macro-autophagy has recently emerged as a major cellular
process regulated by PI3K signaling that affects response to PI3K/
AKT/mTOR inhibitors in both mouse models of cancer and in
primary human cancers [5,16]. Autophagy is an evolutionarily
conserved catabolic process whereby cells degrade and recycle
aggregated protein complexes, poorly functioning organelles and
pathogens allowing cells to survive starvation and other stresses
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[17,18]. The role of macro-autophagy (henceforth referred to as
autophagy) in tumorigenesis and therapy responsiveness is
complex, as it appears to both promote and inhibit tumor growth
and progression, depending on stage of progression, driving
oncogene and tissue type [19,20].
This work shows that the sensitivity of squamous cell carcinoma
cell lines to PI3K and AKT inhibitors is heavily influenced by the
ability to undergo functional macro-autophagy and that sensitivity
can be regulated by modulating autophagy related genes. We
identify loss of ATG7 expression as a means to explain both
abrogated macro-autophagy and increased resistance to PI3K
pathway inhibitors. The effect of ATG7 silencing and autophagy
inhibition on sensitivity to PI3K inhibitors results in accumulation
of p62/SQSTM1, which is associated with increased anti-oxidant
response and tumor cell survival and, in fact, increased p62/
SQSTM1 expression is observed in primary SCCHN tumors.
These results emphasize the importance of understanding the
unique role played by macro-autophagy in specific tumor types
and in response to key therapeutic interventions for each cancer.
Materials and Methods
Cell lines and reagents
CAL27, Detroit 562 (CCL138), and HEK293t cell lines were
purchased from American Tissue Culture Collection (Manassas,
VA), SQ-20B, SCC25, SCC35, SCC28, SCC58, and SCC61 cell
lines [21] were provided by Dr. Ralph Weichselbaum, University
of Chicago. HN5 cells [22] were provided by the Ludwig Institute
for Cancer Research (London, UK). Breast cancer cell lines,
HCC38, T47D, MDA-MB468, HCC1937, SKBR3, MCF-7,
MDA-MB231 and HS578T, were provided by Dr. Kay Macleod,
University of Chicago and were originally purchased from
American Tissue Culture Collection (Manassas, VA). All cell lines
were cultured in culture medium containing 10% fetal bovina
serum and Pen/Strep (concentration).
Phospho-Akt (Ser473), phospho-Akt (Ser308), phospho-S6
Kinase (Ser254/256), phospho-GSK-3beta (Ser9), LC3B
(#3868), ATG7 (#2631), Beclin-1 (#3495), ATG5 (#8540),
ATG12 (#4180), and Rapamycin were purchased from Cell
Signaling Technology Inc (Danvers, MA). p62/SQSTM1
(PM045) antibody was purchased from MBL Co. Antibodies
against alpha-tubulin (sc-8035) were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA), Cyclin D1 (NB 600-584) from
Novus Biologicals, Inc. (Littleton, CO), and HA rat monoclonal
antibody (3F10) from Roche Applied Science (Indianapolis, IN).
IRDye 800 anti-mouse IgM Mu chain specific antibody was
purchased from Rockland Immunochemical for Research (Gil-
bertsville, PA). Other IRDye secondary antibodies were purchase
from Li-Cor Biosciences (Lincoln, NE). Doxycycline Hydrochlo-
ride (#BP2653-1) was purchased from Fisher Scientific.
SAR245408 and SAR245409 were provided by Sanofi-Aventis
Bridgewater, NJ, and MK-2206 was provided by Merck & Co.,
Inc., Rahway, NJ.
ShRNA-p62/SQSTM1 lentiviral vectors and siRNA
transfection
A set of p62/SQSTM11 shRNA vectors (SHCLNG-
NM_003900), and a non-target shRNA control vector were
purchased from Sigma-Aldrich (St. Louis, MO) for the p62/
SQSTM1 knockdown experiments. Lentivirus production and
viral infection were done as previously described [23]. Small
interfering RNA (siRNA) duplexes were purchased from Ambion
(Austin, TX) targeting ATG7 (ID# s20650 and s20651). Negative
Control #1 siRNA was used as control. siRNAs (30 mM per
100 ml transfection solution) were electroporated using Lonza’s
Nucleofector and the Cell Line Neucleofection kit V (Walkersville,
MD) As described in [23]
Expression of p62/SQSTM1 in SCC61 and MCF-7 cells
The vector expressing HA-tagged p62/SQSTM1, pLenti-GIII-
CMV-hSQSTM1-HA, and Lenti-combo packing mix purchased
from Applied Biological Materials Inc. (Richmond, BC, Canada)
were used to transect into 293T cells to produce p62/SQSTM1-
HA lentiviruses for transduction of SCC61 cells. SCC61 cells
stably expressing p62/SQSTM1-HA were selected in growth
medium containing 4 mg/ml of puromycin. For overexpression of
p62/SQSTM1 in MCF-7 cells, pLenti-GIII-hSQSTM1-HA
vector DNA was transfected with TransIT-LT1 (Mirus Bio
LLC, Madison, WI) into MCF-7 cells and the transiently
transfected cells were used for assays.
Establishing inducible knockdown of ATG7 in SCC61 cells
The pTRIPZ-hAtg7shRNA vector, a Tet-On expression vector,
the pGIPZ-non-Silencing control vector, and Trans-Lentiviral
packaging mix were purchased from Fisher Scientific Company
(Hanover Park, IL). Production of lenti-viruses, lentiviral trans-
duction, and selection of puromycin-resistant SCC61 cells were
done as described above. The Tet system approved fetal bovine
serum (Clontech Laboratories, Inc, Mountain View, CA) was used
in culturing the stable SCC61 cell lines and Doxycycline was
added to cell culture (1 mg/ml of final concentration) to induce the
expression of hAtg7 shRNA in cells.
Establishing SCC35-mycAtg7 cell line
A lentiviral vector expressing human ATG7 gene was construct-
ed by ligating the EcoRI-NotI fragment containing myc-hAtg7
from pCMV-myc-Atg7 vector [24] into pCDH-CMV-MCS-EF1-
puro vector. Lentiviruses expressing mycAtg7 were produced as
described above. Transduction of SCC35 cells and selection of
selection of SCC35-mycAtg7 cell line are previously described
[23].
Bisulfite conversion and methylation-specific PCR
Genomic DNA was isolated using Wizard SV Genomic DNA
Purification System (Promega). Bisulfite conversion of genomic
DNA was done with EpiTect Fast Bisulfite kit (Qiagen) following
the manufacture’s recommended protocol. Methylation-specific
PCR was done with HotStar d-Tect polymerase (EpiTect MSP
Kit from Qiagen) and the methylation-specific, unmethylated-
specific, and wild-type primer sets as described in Table S6 in File
S1. PCR condition was 95uC for 10 minutes, 35 cycles of 94uC for
15 seconds, 55uC for 30 seconds, 72uC for 30 seconds, and
finished with an extension at 72uC for 10 min. The Methyl
Primer Express Software v1.0 (Life Technologies, Inc) was used to
predict CpG island and to design PCR primers.
Cell cycle analysis and cell viability assay
Cell cycle analysis was done with Propidium Iodide (PI) staining
as described in [23]. For cell viability assay, 1000–2000 cells were
seeded in 96-well dishes, and the cells were treated with drugs and
assayed with CellTiter-Blue reagent (Promega, Madison, WI) as
described in [23]. GraphPad or Grafit Software was used to
calculate IC50s.
Protein immunoblot analysis
Cell lysis, protein concentration, separation, and transfer were
determined as previously described [23]. Membranes were
p62/SQSTM1 Predicts PI3K Inhibitors Sensitivity
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blocked using blocking buffer (Li-Cor Biosciences, Lincoln, NE).
Secondary antibodies were infrared-labeled. Odyssey Infrared
Imaging system (Li-Cor Biosciences, Lincoln, NB) was used for
protein detection and quantification.
Quantitative real-time PCR
RNA was isolated as previously described [23]. ATG7 RNA was
measured by ATG7 primers TaqMan RNA assay (Applied
Biosystems) and determined by qRT-PCR performed on a
StepOnePlus machine (Applied Biosystems).
Tissue Microarrays (TMA)
Custom human tissue microarrays (TMA) were fabricated in the
Human Tissue Resource Center of the University of Chicago.
Serial sections were prepared from TMA blocks containing
normal, dysplastic, and malignant head and neck tissues cores.
The sections were stained with antibodies against phospho-specific
AKT, p62/SQSTM1, and ATG7 proteins separately. The stained
slides were scanned at 206 using the Aperio ScanScope XT
instrument and were analyzed in ImageScope viewing software
using Genie and a Color Deconvolution macro (a macro is a
modified algorithm). Genie is a pattern recognition algorithm that
was trained to recognize tumor cells present in the tissue. The
Genie macro was applied to the Color Deconvolution macro to
analyze the intensity of tumor cells, ignoring all other cellular types
present in tissue.
Results
SCCHN tumor cells exhibit varying degrees of sensitivity
to PI3K/AKT inhibitors that does not correlate with
PIK3CA mutational status
Activating mutations in PIK3CA have been hypothesized to
predict responsiveness to PI3K inhibitors and there are at least two
SCCHN cell lines, SCC61 (E542K) and Detroit 562 (H1047R),
which harbor such mutations [25]. However, when we screened a
panel of SCCHN cell lines for sensitivity to increasing concentra-
tions of SAR245408, a selective class I PI3K inhibitor, and MK-
2206, an allosteric AKT inhibitor, we observed that PIK3CA
mutational status did not robustly predict drug sensitivity
(Figure 1A, Table S1 in File S1). In fact, the Detroit 562 cell
line was relatively resistant to PI3K pathway inhibitors despite
harboring a PIK3CA mutation suggesting that additional factors
contribute to the sensitivity of tumor cells to this class of agents.
Nonetheless, MK-2206 and SAR245408 specifically and efficiently
inhibited downstream effectors of PI3K, AKT and S6 in File S1,
in SCCHN cells (Figure S1-A in File S1). Thus resistance of
SCCHN cells to the drugs cannot be explained by lack of putative
target inhibition. Furthermore, apoptotic cells represented no
more than 10% of the total cell population upon exposure to MK-
2206 and SAR245408 (Table S2 in File S1) indicating that
apoptosis induction did not contribute to the differences in drug
sensitivity. All cell lines also showed reduced cell cycle progression
in response to drug (Figure S1-B in File S1) as well as reduced
cyclin D1 expression in an equivalent and transient manner
(Figure S2 in File S1). These results indicate that neither apoptosis
induction nor cell cycle differences are determinants of sensitivity
to PI3K pathway inhibitors in SCCHN cell lines and suggest that
other biological processes are more relevant.
Sensitivity to PI3K/AKT Inhibitors is associated with
induction of macro-autophagy
Induction of macro-autophagy is another phenotypic response
to PI3K pathway inhibitors [26,27]. To assess whether differences
in the ability to undergo functional autophagy explained the
observed differential sensitivity of SCCHN cell lines to
SAR245408 and MK2206, we first examined LC3B, a commonly
used marker of autophagosome formation and autophagic flux
[28]. Interestingly, we observed marked differences in baseline
autophagic activity between different SCCHN cell lines
(Figure 1B). For example, the SCC35 cell line showed very low
levels of processed LC3B-II (Figure 1B, lane 1) while SCC61 cells
showed a much higher level of processed LC3B-II (Figure 1B, lane
2). These effects were exaggerated when cells were exposed to
SAR245408, MK2206, or SAR245409, a dual inhibitor of PI3K
and mTOR (Figure 1C). To examine whether the cell lines are
autophagy competent, we measured autophagy flux by treating
cells with bafilomycin A (BA) before harvesting, and we showed
that increased levels of processed LC3B-II in some SCCHN cell
lines (HN5, SCC61, SQ20B, CAL27, and SCC58) following drug
treatment except SCC35. Furthermore, the results reflected
increased autophagic flux since pre-treatment of cells with
bafilomycin A (BA) increased the overall levels of processed
LC3B-II compared to drug treatment alone (Figure 1D). These
results demonstrate that MK-2206 induced autophagic flux to
some degree in all cell lines except SCC35. Although the fold
increase in autophagy flux were higher in cell lines such as HN5,
SQ20B, and CAL27 compared to SCC61 and SCC58, the higher
fold increase can be mostly attributed to low baseline level of
LC3B-II. We analyzed the correlation between baseline levels of
processed LC3B-II (Figure 1B) and the IC50 of each cell line for
PI3K pathway inhibitors and found a negative linear association
(Table S3 in File S1, Figure 1E).
Induction of autophagy by MK-2206 and SAR245408 was
further verified by transmission electron microscopy (TEM) where
we detected a significant increase in large cargo-laden autophago-
somes and autophagolysosomes following treatment with either
inhibitor of the sensitive SCC61 cell line (Figure 2, panels 1–6)
compared to treatment with vehicle control (DMSO). In contrast,
we failed to detect any autophagosomes before or after treatment
of the inhibitor-resistant SCC35 cell line (Figure 2, panels 7–8).
Expression of p62/SQSTM1 has also been utilized as an
indirect measure of autophagy in some cell types since it is a
multifunctional adaptor protein that serves to target certain
cytoplasmic cargo to the autophagosome and is consumed during
autophagic flux [29,30]. Thus, p62/SQSTM1 expression decreas-
es during autophagy induction. Consistently, we observed that
p62/SQSTM1 levels decreased as processed LC3B-II levels
increased in drug-sensitive SCC61 cells in response to treatment
with MK2206 (Figure 3A, left). By contrast, no change in p62/
SQSTM1 expression was detected in the drug-resistant SCC35
cells (Figure 3A, right) and indeed SCC35 cells expressed higher
basal levels of p62/SQSTM1 compared to drug-sensitive SCC61
cells consistent with a defect in autophagy (Figure 3B). These
results suggest that autophagy deficiency in SCC35 cells may lead
to p62/SQSTM1 accumulation and contribute to resistance to
PI3K pathway inhibitors.
Defective autophagy in drug-resistant SCCHN cells is
associated with loss of ATG7 expression
To gain insight into the mechanism of autophagy deficiency in
SCC35 cells, we measured levels of ATG7 and ATG5-ATG12
conjugation in different SCCHN cell lines since ATG7-mediated
p62/SQSTM1 Predicts PI3K Inhibitors Sensitivity
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conjugation of ATG12 to ATG5 is an essential step in
autophagosome formation. We observed robust ATG7 expression
and formation of the ATG5-ATG12 conjugate in drug sensitive
SCC61 cells. However, ATG7 protein was undetectable in the
resistant SCC35 cells consistent with loss of ATG7 expression
(Figure 3C), even though unconjugated ATG5 and ATG12 were
readily detected. Indeed, the absence of ATG7 in SCC35 cells is
consistent with their inability to undergo effective LC3 conversion
(Figure 3A right) and this being the underlying mechanism of
defective autophagy. By contrast, the more sensitive SCC61 cell
line underwent efficient LC3 processing (Figure 3A, left).
ATG7 protein expression was undetectable in SCC35 cell line
(Figure 3D, lane 5) and RT-PCR demonstrated that ATG7 mRNA
in SCC35 cells was also dramatically reduced compared to SCC61
cells (Figure 3E) suggesting reduced transcription of ATG7 in drug
resistant SCC35 cells. We hypothesized that ATG7 was being
epigenetically silenced in SCC35 cells and, using Methyl Express
Primer software, we identified a CpG island near the ATG7
promoter (Figure 3F, top). Indeed, methylation-specific primers
revealed a CpG-region of the ATG7 promoter that is hypermethy-
lated in SCC35 but unmethylated in SCC61 cells (Figure 3F,
bottom) supporting our hypothesis that transcriptional inactivation
of ATG7 in SCC35 cells is likely due to epigenetic silencing of the
ATG7 promoter.
Regulation of ATG7 modulates PI3K/AKT inhibitor
sensitivity
ATG7 plays a critical role in canonical autophagosome
formation and its depletion is predicted to effectively abrogate
autophagy, unless alternative sources of phagophore membranes
are utilized [31,32]. In order to determine whether effective
Figure 1. Autophagy is induced in SCCHN cell lines by MK-2206 and SAR245408 and autophagy competence positively correlates
with drug sensitivity. A) Dose-response curve of SCCHN cell lines to MK-2206 and SAR245408. Cells were treated with the inhibitors for 72 hours
and cell viability were assayed using Cell-Titer Blue reagent as described in Methods. B) SCCHN cell lines show variable autophagic activity defined by
the ratio of LC3-II/LC3-I. The intensity of LC3-I and LC3-II bands were quantified with a Li-Cor imaging scanner. C) Western blots show PI3K/mTOR
inhibitors induce autophagy in several SCCHN cell lines but not in SCC35 cells. D) Effect of MK-2206 and bafilomycin A1 on LC3-II protein in SCCHN
cell lines. Cells were treated for 24 hours and bafilomycin A1 (final concentration 100 nM) was added 4 hours before harvesting. Western blotting was
probed with LC3 antibody. LC3-II was quantified and normalized to tubulin. E) Drug sensitivity to MK-2206 and SAR245408 correlated with intrinsic
autophagy competence.
doi:10.1371/journal.pone.0090171.g001
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autophagy was critical to PI3K and AKT inhibitor sensitivity, we
depleted ATG7 in the more sensitive SCC61 cells using siRNA
and an inducible Atg7shRNA lentiviral vector. When ATG7 is
significantly depleted in SCC61 cells, the LC3-II level is
dramatically reduced (Figure 4A). However, stable knockdown of
ATG7 with constitutively expressed Atg7shRNA in SCC61 cells
was incompatible with cell survival (data not shown). We therefore
utilized an inducible vector, pTRIPZ-hAtg7shRNA, and estab-
lished a stable SCC61 cell line where induced expression of
hAtg7shRNA with doxycycline significantly reduced ATG7
protein (.80%) compared to untreated controls (Figure 4B, top).
Induced ATG7 depletion resulted in increased free ATG5 in cells
treated with doxycycline (Fig. 4B, bottom-right). In addition,
bafilomycin A1 treatment increased p62/SQSTM1 protein
expression (Figure 4B, bottom-left) consistent with a block in
autophagolysosome formation and, more importantly, p62/
SQSTM1 expression concomitantly increased in ATG7 depleted
cells. Taken together, these results support that knockdown of
ATG7 in SCC61 cells significantly disrupted autophagy. Signif-
icantly, doxycycline treated SCC61 cells were significantly more
resistant to MK-2206 compared to no doxycycline control with
IC50s of 1.56 mM and 0.43 mM, respectively (Figure 4C). These
results demonstrate that inhibition of autophagy in SCC61 cells
promotes drug resistance and indicates that autophagy is required
for sensitivity to PI3K/AKT inhibitors.
Regulation of p62/SQSTM1 modulates PI3K/AKT inhibitor
sensitivity
As demonstrated above and previously described [30,33], p62/
SQSTM1 is consumed when cells undergo autophagy. Thus we
postulated that autophagy prevented resistance to PI3K pathway
inhibitors by promoting p62/SQSTM1 turnover. We investigated
the role of p62/SQSTM1 in drug resistance in SCCHN by
altering expression of p62/SQSTM1. Stably depleting p62/
SQSTM1 in SCC35 derived cells, SCC35p62KD, resulted in a
60–70% reduction in p62/SQSTM1 protein expression
(Figure 5A) which led to a significant increase in sensitivity of
these cells to MK-2206 compared to SCC35-Control cells
expressing the control scrambled shRNA (Figure 5B). Importantly,
SCC35p62KD cells now showed similar sensitivity to MK2206 as
drug sensitive SCC61 cells (Figure 5B). These results are consistent
with the hypothesis that relatively high expression of p62/
SQSTM1, arising in SCC35 cells secondary to a defect in
autophagy, drives resistance to PI3K pathway inhibitors.
We then asked whether p62/SQSTM1 protein expression is a
predictive marker for PI3K pathway inhibitors in SCCHN cell
lines. We determined the expression of p62/SQSTM1 protein in
SCCHN cell lines (Figure 5C, top) and found a positive correlation
with sensitivity to the PI3K inhibitor SAR245408 and a similar
trend to MK-2206 (Table S4 in File S1). To test these findings in
other tumor cell types, we expanded our analysis to a panel of
breast cancer cell lines where we detected a range of p62/
SQSTM1 protein expression (Figure 5C, middle) and drug
sensitivity to MK2206 (Figure 5C, bottom). Interestingly, the
positive correlation found in SCCHN cell lines between p62/
SQSTM1 expression and PI3K/AKT inhibitors sensitivity was
also observed in breast cancer cells (Table S5 in File S1). These
results indicate that resistance to PI3K and AKT inhibitors is
associated with higher levels of p62/SQSTM1 in both SCCHN
and breast cancer cells. We then investigated mechanisms of
resistance of PI3K pathway inhibitor mediated by p62/SQSTM1
in SCCHN cells. p62/SQSTM1 is a multi-functional adaptor
protein that interacts with molecules involved in inflammation and
oxidative stress [29,34] in addition to autophagy. For example,
p62/SQSTM1 stabilizes Nrf2 and promotes its transcriptional
activation of antioxidant and detoxifying genes, such as NQO1
[35,36]. Given that we observe accumulation of p62/SQSTM1 in
autophagy-deficient and drug resistant SCCHN cell lines, we
investigated whether expression of Nrf2-regulated genes was
influenced by p62/SQSTM1 in these cell lines. Indeed, abrogated
expression of p62/SQSTM1 reduced expression of both Nrf2
(Figure 5D) and its target gene, NQO1 (Figure 5E) in SCC35 cells
compared to baseline. Conversely, ectopic expression of HA-
tagged p62/SQSTM1 in relatively drug sensitive cell lines such as
SCC61 and MCF-7 (Figure 6A) rendered these cells more resistant
to MK-2206 compared to control (Figure 6B) Taken together,
these results indicate that p62/SQSTM1 is a predictive marker of
resistance to PI3K pathway inhibitors in SCCHN and breast
cancer cell lines, and that autophagy deficiency can lead to
increased expression of p62/SQSTM1, suggesting that elevation
of p62/SQSTM1 in cells can promote resistance through
increased Nrf2 activity and expression of Nrf2-regulated anti-
oxidant genes.
Expression of Autophagy Related Proteins in SCCHN
Tissue
The data above support a mechanistic role for autophagy and
p62/SQSTM1 in determining the response of a subset of SCCHN
cells to PI3K pathway inhibitors. In order to determine whether
this has relevance to primary human SCCHN, we created tissue
microarrays consisting of normal (n = 76), dysplastic (n = 87), and
malignant (n = 199) oral mucosal tissue and performed immuno-
histochemical staining for autophagy related proteins. As expected,
AKT phosphorylation increased steadily from normal to dysplastic
to oral cancerous tissues reflecting progressive activation of the
PI3K pathway during malignant progression (Figure 7A). In
conjunction with a rise in phospho-AKT, which would be
Figure 2. Induction of autophagy by MK-2206 and SAR245408
in SCC61 cells, not in SCC35 cells, is shown by transmission
electron microscopy. Cells were treated with the inhibitors for
24 hours before harvesting and fixation. Autophagosomes (AP) and
autophagolysosomes (AL) are indicated by arrows.
doi:10.1371/journal.pone.0090171.g002
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Figure 3. SCC35 cell line is deficient in ATG7 expression and is macro-autophagy deficient. Time course of autophagy induction by MK-
2206 in SCC61 (A) and SCC35 (B) cells. Western blots show LC3-II and p62/SQSTM1 levels from cells treated with MK-2206 (5 mM) at the time points
indicated. Fold change was calculated by the ratio of the MK-2206 treated to untreated controls (C). C) Formation of ATG5-ATG12 conjugates in
SCCHN cell lines. Western blotting was probed sequentially with ATG12 and ATG7 antibodies (top). The same lysates were analyzed with an ATG5
antibody (bottom). D) ATG7 protein expression in a panel of SCCHN cell lines by western blotting. A non-specific band was detected below the ATG7
protein. E) Detection of ATG7 mRNA by Real-time PCR in both untreated (control) and MK-2206 treated SCC35 and SCC61 cells. F) Methylation-
specific PCR amplification of the 59 untranslated region of ATG7 gene in SCC35 and SCC61 cells. Untreated and bisulfite treated SCC35 and SCC61
genomic DNAs were used as templates for PCR amplification. The PCR products were analyzed on a 1.2% agrose gel. The unmodified genomic DNA
was used with the wild type primers and bisulfite treated genomic DNAs were used for both unmethylated and methylated specific primers. The
primer region contains 2 CpG sites as listed in Methods.
doi:10.1371/journal.pone.0090171.g003
p62/SQSTM1 Predicts PI3K Inhibitors Sensitivity
PLOS ONE | www.plosone.org 6 March 2014 | Volume 9 | Issue 3 | e90171
expected to inhibit autophagy, an increase in p62/SQSTM1 was
also observed in primary SCCHN cancer compared to normal
and dysplastic tissues (Figure 7B and 7C). p62/SQSTM1
expression in cancers was present in both nucleus and cytoplasm
consistent with the finding that p62/SQSTM1 protein contains
two nuclear localization signals and a nuclear export signal and
that the protein can shuttle between nucleus and cytoplasm [37].
Our data, therefore, support a model in which accumulation of
p62/SQSTM1 in SCCHN cancers promotes resistance to PI3K
pathway inhibitors.
Figure 4. Regulation of ATG7 modulates drug sensitivity in SCC61. A) Depletion of ATG7 protein expression in SCC61 cells reduced LC3-II.
SCC61 cells were transfected with control siRNA or ATG7 siRNA and analyzed by western blotting. LC3-II protein was quantified and the results shown
graphically. B) Generation of conditional knockdown of ATG7 in SCC61-hAtg7shRNA cells. Doxycycline (1 mg/ml) was added for a week to knockdown
ATG7 expression. Western blotting for ATG7 expression and graphic representation of quantified ATG7 are shown (top panel). The SCC61-
hAtg7shRNA cells were treated with MK-2206 and Bafilomycin as described in Methods. Western blots show ATG7, ATG5, ATG5-ATG12 conjugates,
and p62/SQSTM1 protein. p62/SQSTM1 quantification was normalized to tubulin and fold change was compared to untreated control (first lane). C)
ATG7 depleted SCC61 cells are significantly more resistant to MK-2206. Cell viability assays were preformed in the presence of MK-2206 (5 mM) or the
vehicle control (DMSO).
doi:10.1371/journal.pone.0090171.g004
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Discussion
This work demonstrates, for the first time, a relationship
between autophagy deficiency and resistance to a specific drug
class, namely PI3K pathway inhibitors. Interestingly, this resis-
tance was accompanied by accumulation of p62/SQSTM1 and
partially reversed by its depletion. Moreover, tumor cell lines that
are autophagy competent were more sensitive to PI3K inhibition,
which is also reversed by depletion of obligatory macro-autophagy
proteins. The findings that SCCHN display increased p62/
SQSTM1 expression compared to normal and dysplastic tissue
suggests that these findings are clinically meaningful and that there
are many cancers that will be inherently resistant to PI3K
inhibition due to defects in autophagy. In fact, alterations of ATG7
gene were detected in TCGA Head and Neck Squamous Cell
Carcinoma samples as we analyzed the data set using the cBio
Cancer Genomic Portal (cBioPortal) [38]. These alterations
include three cases of putative homozygous deletion, 27 cases of
mRNA down-regulation (one case overlapped with homologous
deletion), and two cases of mRNA up-regulation (Figure S3-A in
File S1). Interestingly, overall survival from cases with alterations
in ATG7 was lower than cases without alterations (Figure S3-B in
File S1) with median survival of 15 versus 28 months, respectively
(log rank p-value 0.048964). Unfortunately, p62/SQSTM1
protein expression data are not available precluding an analysis
of the relationship to ATG7 alterations. Taken together, these
results support the hypothesis that autophagy competence and
p62/SQSTM1 could be used to stratify certain cancers for their
response to specific therapies. This is in contrast to other published
work where autophagy is more generally shown to promote drug
Figure 5. Effects of down regulation of p62/SQSTM1 in SCC35 cells and association of p62/SQSTM1protein level with drug
resistance in both SCCHN and breast cancer cells. A) Western blotting shows knockdown of p62/SQSTM1 in SCC35-p62KD cell line compared
to SCC35-control (left). The p62/SQSTM1 bands were quantified and shown graphically on the right. B) Dose-response curves of SCC35-p62KD,
SCC35-control, parental cells (SCC35), and SCC61 cells to MK-2206. C) Detection of p62/SQSTM1 protein expression in panels of SCCHN (Top) and
breast cancer cell lines (Middle) by western blotting as described in Methods. Dose-responsive curves of the panel of breast cancer cell lines treated
with MK-2206 (Bottom). D and E) Reduced expression of Nrf2 (D) and NQO1 (E) in SCC35-p62KD and SCC35-control cells. Western blotting shows
duplicate samples from each derived cell line. Graph represents quantified fold change normalized to control.
doi:10.1371/journal.pone.0090171.g005
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resistance [39] and underscores the multi-faceted role of autoph-
agy in cancer.
The novel observation that ATG7 expression can be lost was
unexpected. ATG7 is required during autophagosome formation
at two critical points: formation of ATG5-ATG12 conjugates and
incorporation of LC3 into the membrane. Consistently, loss of
ATG7 expression in SCCHN cells was associated with defects in
autophagy. Given that targeted deletion of Atg7 in mice results in
perinatal lethality and tissue specific deletion causes marked
defects in both liver and brain [40], it was initially surprising that
SCC35 cells express nearly undetectable levels of ATG7. Given
their altered metabolism and increased cellular dysfunction, it
might have been predicted that tumor cells would be critically
dependent on ATG7 and autophagy for homeostasis and survival.
ATG7 has been shown to have functions that are independent of
macro-autophagy, including potentiating non-apoptotic cell death
by caspase-8 [41] and regulation of p53 activity [42] and it is
possible that loss of ATG7 in tumors is selected for to prevent
autophagy-independent functions. Interestingly, when we attempt-
ed to rescue autophagic competence in SCC35 cells by ectopically
expressing ATG7 (Figure S4 in File S1), we could not induce
autophagy or reverse drug resistance. The resistance phenotype, in
fact, was only reversed by abrogating p62/SQSTM1 expression,
which, in turn can be regulated by several processes beyond
autophagy. It is likely that different SCCHN tumors stabilize p62/
SQSTM1 and activate Nrf2 through other mechanisms. In fact,
recent data demonstrate that some SCCHN harbor activating
mutations in Nrf2 [15] suggesting that the p62/SQSTM1-Nrf2
axis could be a prime target for therapy.
Macro-autophagy is known to play a critical role in tissue
homeostasis and it has been suggested that tumor cells rely heavily
on macro-autophagy for metabolites, energy, and to remove the
increased levels of protein aggregates and dysfunctional organelles
that accumulate more rapidly in tumor cells [43,44]. One key
avenue of future investigation will therefore be to understand how
tumor cells compensate for defects in macro-autophagy in order to
degrade cytoplasmic aggregates and organelles. Although macro-
autophagy has been well described [44,45], other forms of
autophagy are also known to play a role in cellular housekeeping.
Recently, chaperone mediated autophagy (CMA) was shown to be
activated in lung and melanoma cell lines and to promote tumor
cell growth [46]. Microautophagy involves direct engulfment of
cytoplasmic cargo and plays an important role in maintaining
nuclear and organelle function. However, whether microauto-
phagy can compensate for deficient macro-autophagy and its
broader role in cancer has not been examined. Nonetheless, if
cancer cells that are macro-autophagy deficient are more
dependent on other forms of autophagy, such as CMA or
microautophagy for survival, [47], then these compensating
pathways may represent novel therapeutic targets in cancer.
If macro-autophagy does emerge as a meaningful readout of
therapeutic efficacy in cancers as our work would suggest,
predictive biomarkers of autophagy efficiency will be essential.
Here we show that expression of specific autophagy related
proteins are associated with sensitivity to PI3K pathway inhibitors.
However, measuring autophagy competence or autophagic flux in
situ in tumors is more complex. Like any dynamic process, levels of
autophagy will be subject to change in response to various
temporal, environmental, and physiological stresses. Finding the
Figure 6. Overexpression of p62/SQSTM1 increases drug resistance in both SCCHN and breast cancer cells. A) MCF-7 cells were
transiently transfected with p62/SQSTM1 expressing vector and SCC61 cells were stably transduced with lentivirus carrying the same p62/SQSTM1
vector. Western blotting shows the ectopically expressed p62/SQSTM1-HA protein detected with HA antibody (3F10). The same blot was reprobed
with p62/SQSTM1 antibody to show the total p62/SQSTM1 protein expression in both cell types. B) Cell viability assays demonstrate that p62/
SQSTM1 expression increases drug resistance in both MCF-7 and SCC61 cell lines.
doi:10.1371/journal.pone.0090171.g006
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optimal set of biomarkers has proven challenging. While electron
microscopy has been considered the gold standard for evaluating
autophagy in situ, its application to the clinical situation is
logistically difficult [48]. Notwithstanding, the data here suggest
that p62/SQSTM1, LC3-II, ATG7, and potentially others are
candidate pharmacodynamic markers for drugs, including PI3K
pathway inhibitors that exert their effects through modulating
autophagy.
While autophagy was once considered a form of programmed
cell death, it is now recognized that this process functions as an
important survival mechanism during cellular stress. The finding
that autophagy can be defective in cancer cells and a compromised
ability to undergo autophagy is mechanistically related to
therapeutic resistance must now be integrated into our under-
standing of this process in malignant disease and tested in clinical
trials. These results, of course, open new avenues of exploration
and exploitation of specific phenotypes in the development of
novel therapies.
Supporting Information
File S1 Figure S1. A) MK-2206 and SAR245408 inhibit AKT
and S6 phosphorylation. B) MK-2206 and SAR245408 efficiently
induce G1-arrest in SCC61 cells but not in SCC35 cells. Figure
S2. Effect of MK-2206 and SAR245408 on AKT phosphorylation
and cyclin D1 protein in SCCHN cell lines. Figure S3. Alterations
of ATG7 gene in the TCGA Squamous Cell Carcinoma of Head
and Neck (SCCHN) database and overall survival. Table S1. IC50
of MK-2206 and SAR245408 in SCCHN cell lines. Table S2.
Apoptotic assay after 48 hours of treatment with MK02206 or
SAR245408. The values are expressed as percentage of total cell
number counted. Table S3. Intrinsic autophagy competence
determined by LC3-II to LC3-I ratio and IC50 of respective agents
in SCCHN cell lines. Table S4. Relationship between p62/
SQSTM1 protein expression and IC50 in SCCHN cell lines.
Pearson rank correlation was used to calculate correlation. Table
S5. Relationship between p62/SQSTM1 protein expression and
IC50 in breast cancer cell lines. Pearson rank correlation was used
to calculate correlation. Table S6. Primer sequences for ATG7
MSP analysis.
(DOC)
Figure 7. Expression of phospho-AKT and p62/SQSTM1 in tissue microarrays of normal, dysplastic, and malignant oral mucosa. A)
Expression of phospho-AKT. Tissue microarrays were stained with phospho-AKT specific antibodies and scored as described in Methods. A total of
362 individual samples were analyzed which included 76 normal, 87 dysplasia, and 199 cancer samples. Histograms show score distribution from
cancer samples. B) Expression of p62/SQSTM1. The same tissue microarrays were stained with p62/SQSTM1 antibody and scored as described in
Methods. Histograms show score distribution from cancer samples. C) Images (206magnification) of representative immunohistochemical staining
in normal, dysplasia, and cancer tissues obtained from the same patient.
doi:10.1371/journal.pone.0090171.g007
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